Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 12/20 | 0.42 |
| ▸ | PPARD | Q03181 | 10/20 | 0.42 |
| ▸ | PPARG | P37231 | 6/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | FBP1 | P09467 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1549559 | 0.91 | PPARA (0.51) | PPARAPPARDPPARG | |
| SCHEMBL1549943 | 0.87 | PPARA (0.56) | PPARAPPARDPPARGEPHX2NR1H4 | |
| SCHEMBL1550194 | 0.86 | EPHX2 (0.40) | PPARAPPARDPPARGEPHX2NR1H4 | |
| SCHEMBL1549631 | 0.85 | PPARA (0.49) | PPARAPPARDPPARGCYP3A4ROCK2 | |
| SCHEMBL1549843 | 0.83 | PPARD (0.42) | PPARAPPARDPPARGEPHX2NR1H4 | |
| SCHEMBL6106937 | 0.82 | PPARA (0.57) | PPARAPPARDPPARGLMNAABCB11 | |
| SCHEMBL1550809 | 0.81 | EPHX2 (0.40) | PPARAPPARDPPARGEPHX2NR1H4 | |
| SCHEMBL1550163 | 0.81 | EPHX2 (0.40) | PPARAPPARDPPARGEPHX2NR1H4 | |
| SCHEMBL1549944 | 0.81 | PPARA (0.48) | PPARAPPARDPPARGLMNA | |
| SCHEMBL1549989 | 0.81 | EPHX2 (0.39) | PPARAPPARDPPARGEPHX2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115611-B2 | Phenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1682508-A1 | PHENYL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005049573-A1 | PHENYL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| US-20050096337-A1 | Phenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096337-A1 | Phenyl derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | PPARA 2/4885PPARD 1/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.